Daniel H. Li

发表

Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapy

R. Hevner, G. Ishak, M. Jensen, 2019, Annals of neurology.

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

M. Wurfel, D. Maloney, C. Turtle, 2017, Cancer discovery.

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Daniel Li, Xueyan Chen, M. Wurfel, 2017, Blood.

Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure.

D. Maloney, C. Turtle, S. Riddell, 2020, Blood.

Preemptive Mitigation of CD19 CAR T Cell Cytokine Release Syndrome Without Attenuation of Anti-Leukemic Efficacy.

M. Jensen, A. Taraseviciute, Francesco Ceppi, 2019, Blood.

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

L. Deangelis, M. Gonen, M. Sadelain, 2018, Cancer discovery.

CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia

S. Heimfeld, D. Maloney, C. Turtle, 2016 .

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

S. Riddell, K. Kelly-Spratt, A. Oron, 2017, Blood.

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

J. Byrd, S. Heimfeld, B. Wood, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL.

M. Sadelain, R. Brentjens, B. Sénéchal, 2017 .

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Michael L. Wang, L. Gordon, D. Maloney, 2017 .

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

A. Oron, M. Jensen, O. Finney, 2016 .

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

D. Maloney, C. Turtle, S. Riddell, 2017, Blood.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Daniel Li, Jianhong Cao, Xueyan Chen, 2016, The Journal of clinical investigation.

CD19 CAR T cell product and disease attributes predict leukemia remission durability.

R. Orentas, M. Jensen, O. Finney, 2019, The Journal of clinical investigation.

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

D. Maloney, C. Turtle, S. Riddell, 2017, Blood.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Michael L. Wang, L. Gordon, D. Maloney, 2020, The Lancet.

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

S. Heimfeld, B. Wood, D. Maloney, 2016, Science Translational Medicine.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

D. Maloney, J. Kuruvilla, G. Cartron, 2022, Experimental Hematology & Oncology.

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.

D. Maloney, C. Turtle, S. Riddell, 2018 .

in adult B cell ALL patients

S. Heimfeld, B. Wood, D. Maloney, 2016 .

Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells.

M. Sadelain, R. Brentjens, B. Sénéchal, 2017 .

Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose

S. Heimfeld, D. Maloney, C. Turtle, 2016 .

Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells.

K. Loeb, S. Heimfeld, B. Wood, 2016 .

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Michael L. Wang, L. Gordon, D. Maloney, 2019, Blood.

High Durable CR Rates and Preliminary Safety Profile for JCAR017 in R/R Aggressive B-NHL (TRANSCEND NHL 001 Study): A Defined Composition CD19-Directed CAR T Cell Product with Potential for Outpatient Administration

Michael L. Wang, L. Gordon, D. Maloney, 2018 .

High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration.

Michael L. Wang, L. Gordon, D. Maloney, 2018 .

Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells.

M. Wurfel, D. Maloney, C. Turtle, 2017 .

Neurotoxicity Associated with CD19-specific Chimeric Antigen Receptor T cell Therapy for Adult Acute Lymphoblastic Leukemia (B-ALL) (S23.008)

M. Sadelain, B. Sénéchal, B. Santomasso, 2018, Neurology.

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

Michael L. Wang, L. Gordon, D. Maloney, 2017 .

Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy.

M. Sadelain, R. Brentjens, B. Sénéchal, 2017 .

CD19 CAR T cell product and disease attributes predict leukemia remission durability.

R. Orentas, M. Jensen, O. Finney, 2019, The Journal of clinical investigation.

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

R. Orentas, M. Jensen, O. Finney, 2018, Blood.